
Women Infertility Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Women Infertility Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Drugs In Development, 2022, provides an overview of the Women Infertility (Women's Health) pipeline landscape.
Infertility refers to failure to conceive over the course of one full year. Women infertility is caused due to damage of fallopian tubes, ovulation disorders (polycystic ovary syndrome) and endometriosis. Symptoms include abnormal periods, weight gain, back pain, pelvic pain, and cramping. Risk factor of infertility includes smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes medications to stimulate ovulation and hormone therapies.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Women Infertility - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 26, 11, 1, 2, 28, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 4 molecules, respectively.
Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Drugs In Development, 2022, provides an overview of the Women Infertility (Women's Health) pipeline landscape.
Infertility refers to failure to conceive over the course of one full year. Women infertility is caused due to damage of fallopian tubes, ovulation disorders (polycystic ovary syndrome) and endometriosis. Symptoms include abnormal periods, weight gain, back pain, pelvic pain, and cramping. Risk factor of infertility includes smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes medications to stimulate ovulation and hormone therapies.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Women Infertility - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 26, 11, 1, 2, 28, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 4 molecules, respectively.
Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
222 Pages
- Introduction
- Global Markets Direct Report Coverage
- Women Infertility – Overview
- Women Infertility – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Women Infertility – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Women Infertility – Companies Involved in Therapeutics Development
- AlphaMab Co Ltd
- Amega Biotech
- Anelleo Inc
- Aprilbio Co Ltd
- Aptorum Group Ltd
- ASKA Pharmaceutical Holdings Co Ltd
- Bayer AG
- BCI Pharma SA
- Beijing FuKangren Bio-pharm Tech Co Ltd
- Beijing SL Pharmaceutical Co Ltd
- Bharat Serums And Vaccines Ltd
- Bol Pharma
- Bopin (Shanghai) Biomedical Technology Co Ltd
- Chugai Pharmaceutical Co Ltd
- Context Therapeutics Inc
- Daewoong Pharmaceutical Co Ltd
- Egret Therapeutics Inc
- Eikonoklastes Therapeutics Inc
- ElexoPharm GmbH
- Endomet Biosciences Inc
- Enteris BioPharma Inc
- Eurofarma Laboratorios SA
- Evestra Inc
- Evotec SE
- Ferring International Center SA
- Ferring Pharmaceuticals Inc
- Forendo Pharma Ltd
- GeneScience Pharmaceuticals Co Ltd
- Genome & Co
- Glycotope GmbH
- Hangzhou Metai Pharmaceutical Technology Co Ltd
- Hope Medicine Inc
- Igenomix SL
- Igyxos SA
- Immunitor Inc
- Insud Pharma
- Ironwood Pharmaceuticals Inc
- Isifer AB
- Jiangsu Hengrui Medicine Co Ltd
- Kissei Pharmaceutical Co Ltd
- Livzon Pharmaceutical Group Co Ltd
- Luye Pharma Group Ltd
- Medibiofarma SL
- Mithra Pharmaceuticals SA
- Mitsubishi Tanabe Pharma Corp
- Myovant Sciences Ltd
- Navad Life Sciences Pte Ltd
- Neuromagen Pharma Ltd
- Nippon Shinyaku Co Ltd
- NutriBand Inc
- ObsEva SA
- Oxolife SL
- Pangen Biotech Inc
- Park of Active Molecules
- Pharmasyntez
- Predictive Therapeutics LLC
- PregLem SA
- Reven Holdings Inc
- Shandong TheraWisdom Biopharma Co Ltd
- Shanghai Jing Ze Biotechnology Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Suzhou JiSheng Pharmaceutical Co Ltd
- SYNG Pharmaceuticals Inc
- Synokem Pharmaceuticals Ltd
- Takeda Pharmaceutical Co Ltd
- Temple Therapeutics BV
- TiumBio Co Ltd
- Trophogen Inc
- Unicohealth Pharma Co Ltd
- ValiRx Plc
- Viramal Ltd
- Xbrane Biopharma AB
- Women Infertility – Drug Profiles
- (drospirenone + estetrol) – Drug Profile
- (estradiol + norethindrone acetate + relugolix) – Drug Profile
- adezmapimod – Drug Profile
- AGS-534 – Drug Profile
- AKP-501 – Drug Profile
- AMY-109 – Drug Profile
- barusiban – Drug Profile
- BAY-2328065 – Drug Profile
- BAY-2395840 – Drug Profile
- Biologic to Activate GDF9 for Women Infertility – Drug Profile
- BOLDPo-08 – Drug Profile
- CTX-30916 – Drug Profile
- danazol – Drug Profile
- drospirenone – Drug Profile
- Drug 3 for Endometriosis – Drug Profile
- Drug 4 for Endometriosis – Drug Profile
- Drug to Inhibit C-Jun for Endometriosis – Drug Profile
- Drugs for Pre-Eclampsia and Women Infertility – Drug Profile
- DWJ-1483 – Drug Profile
- EC-313 – Drug Profile
- estradiol sulfamate – Drug Profile
- ET-201 – Drug Profile
- FE-999302 – Drug Profile
- FE-999310 – Drug Profile
- follicle stimulating hormone – Drug Profile
- follicle stimulating hormone biobetter – Drug Profile
- follicle stimulating hormone biosimilar – Drug Profile
- follitropin alfa biosimilar – Drug Profile
- follitropin delta – Drug Profile
- FOR-6219 – Drug Profile
- FSH-01 – Drug Profile
- FSH-GEX – Drug Profile
- GEN-004 – Drug Profile
- GENI-401 – Drug Profile
- Gensci-050 – Drug Profile
- Gensci-062 – Drug Profile
- Gensci-068 – Drug Profile
- goserelin – Drug Profile
- goserelin acetate – Drug Profile
- GXP-1 – Drug Profile
- HMI-115 – Drug Profile
- IGX-1 – Drug Profile
- IGX-12 – Drug Profile
- Isifera – Drug Profile
- IW-3300 – Drug Profile
- JZB-30 – Drug Profile
- kisspeptin-54 – Drug Profile
- leuprolide – Drug Profile
- leuprolide acetate – Drug Profile
- linzagolix choline – Drug Profile
- LM-001 – Drug Profile
- MBF-251 – Drug Profile
- medroxyprogesterone acetate SR – Drug Profile
- Menopur – Drug Profile
- MIA-602 – Drug Profile
- MT-2990 – Drug Profile
- MVT-602 – Drug Profile
- NA-0116 – Drug Profile
- NCE-403 – Drug Profile
- NHP-07 – Drug Profile
- NLS-1 – Drug Profile
- nolasiban – Drug Profile
- NS-580 – Drug Profile
- OXO-001 – Drug Profile
- P2X4 Antagonist – Drug Profile
- PAM-8 – Drug Profile
- Peptide to Agonize FSH Receptor for Women Infertility – Drug Profile
- Peptides for Endometriosis – Drug Profile
- progesterone – Drug Profile
- quinagolide ER – Drug Profile
- Recombinant Protein to Agonize AMHR2 for Oncology and Women's Health – Drug Profile
- Recombinant Protein to Agonize FSHR for Women Infertility – Drug Profile
- Recombinant Protein to Agonize PEDF for Women's Health – Drug Profile
- relugolix – Drug Profile
- RPOT-1005a – Drug Profile
- SAL-016 – Drug Profile
- SHR-7280 – Drug Profile
- SJ-02 – Drug Profile
- Small Molecule 2 for Endometriosis and Chronic Cough – Drug Profile
- Small Molecule to Activate Telomerase for Men Infertility and Women Infertility – Drug Profile
- Small Molecule to Inhibit Microsomal Prostaglandin E Synthase 1 for Endometriosis – Drug Profile
- Small Molecules for Endometriosis, Idiopathic Pulmonary Fibrosis (IPF) and Metastatic Brain Tumor – Drug Profile
- Small Molecules for Female Infertility – Drug Profile
- Small Molecules for Women Infertility – Drug Profile
- Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis – Drug Profile
- Small Molecules to Inhibit CSF1R for Breast Cancer and Endometriosis – Drug Profile
- Small Molecules to Inhibit HSD17B1 for Endometriosis – Drug Profile
- SP-012 – Drug Profile
- SR-16234 – Drug Profile
- Stem Cell Therapy for Women Infertility – Drug Profile
- TR-44701 – Drug Profile
- triptorelin – Drug Profile
- triptorelin acetate ER – Drug Profile
- triptorelin acetate SR – Drug Profile
- TTX-334 – Drug Profile
- TWP-201 – Drug Profile
- UN-008 – Drug Profile
- V-Endo – Drug Profile
- VAL-201 – Drug Profile
- VAL-301 – Drug Profile
- Women Infertility – Dormant Projects
- Women Infertility – Discontinued Products
- Women Infertility – Product Development Milestones
- Featured News & Press Releases
- May 09, 2022: Ironwood Pharmaceuticals to present new IW-3300 data at Digestive Disease Week 2022
- May 09, 2022: FDA extends review period for Pfizer-Myovant’s sNDA for Myfembree
- Apr 28, 2022: BioInvent receives milestone payment from Bayer/Hope Medicine licensing agreement
- Apr 12, 2022: Enteris BioPharma announces acceptance of two abstracts for presentation at ENDO 2022 Annual Conference
- Apr 12, 2022: Myovant Sciences and Pfizer provide update on supplemental new drug application for MYFEMBREE for the management of moderate to severe pain associated with endometriosis
- Mar 22, 2022: ObsEva announces additional efficacy results for linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
- Jan 06, 2022: ObsEva announces positive topline results for Linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial in patients with moderate-to-severe endometriosis-associated pain
- Dec 10, 2021: ObsEva hosts symposium and presents clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
- Dec 02, 2021: ObsEva announces symposium and presentation of clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
- Oct 19, 2021: Myovant Sciences and Pfizer present data on Relugolix combination therapy from studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
- Oct 14, 2021: Ferring Pharmaceuticals to present new reproductive medicine data at ASRM 2021 Scientific Congress & Expo
- Oct 04, 2021: Enteris BioPharma announces successful completion of phase 1 clinical trial of optimized Peptelligence oral leuprolide
- Sep 09, 2021: Myovant Sciences and Pfizer announce FDA acceptance of supplemental new drug application for MYFEMBREE for the management of moderate to severe pain associated with endometriosis
- Aug 03, 2021: Notice of start of domestic phase III clinical trial of developed product (FSN-013)
- Jul 06, 2021: ValiRx provides update on Patent status of VAL301
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Women Infertility, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Universities/Institutes, 2022
- Table 7: Products under Development by Companies, 2022
- Table 8: Products under Development by Companies, 2022 (Contd..1)
- Table 9: Products under Development by Companies, 2022 (Contd..2)
- Table 10: Products under Development by Companies, 2022 (Contd..3)
- Table 11: Products under Development by Companies, 2022 (Contd..4)
- Table 12: Products under Development by Companies, 2022 (Contd..5)
- Table 13: Products under Development by Universities/Institutes, 2022
- Table 14: Number of Products by Stage and Target, 2022
- Table 15: Number of Products by Stage and Mechanism of Action, 2022
- Table 16: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 17: Number of Products by Stage and Route of Administration, 2022
- Table 18: Number of Products by Stage and Molecule Type, 2022
- Table 19: Women Infertility – Pipeline by AlphaMab Co Ltd, 2022
- Table 20: Women Infertility – Pipeline by Amega Biotech, 2022
- Table 21: Women Infertility – Pipeline by Anelleo Inc, 2022
- Table 22: Women Infertility – Pipeline by Aprilbio Co Ltd, 2022
- Table 23: Women Infertility – Pipeline by Aptorum Group Ltd, 2022
- Table 24: Women Infertility – Pipeline by ASKA Pharmaceutical Holdings Co Ltd, 2022
- Table 25: Women Infertility – Pipeline by Bayer AG, 2022
- Table 26: Women Infertility – Pipeline by BCI Pharma SA, 2022
- Table 27: Women Infertility – Pipeline by Beijing FuKangren Bio-pharm Tech Co Ltd, 2022
- Table 28: Women Infertility – Pipeline by Beijing SL Pharmaceutical Co Ltd, 2022
- Table 29: Women Infertility – Pipeline by Bharat Serums And Vaccines Ltd, 2022
- Table 30: Women Infertility – Pipeline by Bol Pharma, 2022
- Table 31: Women Infertility – Pipeline by Bopin (Shanghai) Biomedical Technology Co Ltd, 2022
- Table 32: Women Infertility – Pipeline by Chugai Pharmaceutical Co Ltd, 2022
- Table 33: Women Infertility – Pipeline by Context Therapeutics Inc, 2022
- Table 34: Women Infertility – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Table 35: Women Infertility – Pipeline by Egret Therapeutics Inc, 2022
- Table 36: Women Infertility – Pipeline by Eikonoklastes Therapeutics Inc, 2022
- Table 37: Women Infertility – Pipeline by ElexoPharm GmbH, 2022
- Table 38: Women Infertility – Pipeline by Endomet Biosciences Inc, 2022
- Table 39: Women Infertility – Pipeline by Enteris BioPharma Inc, 2022
- Table 40: Women Infertility – Pipeline by Eurofarma Laboratorios SA, 2022
- Table 41: Women Infertility – Pipeline by Evestra Inc, 2022
- Table 42: Women Infertility – Pipeline by Evotec SE, 2022
- Table 43: Women Infertility – Pipeline by Ferring International Center SA, 2022
- Table 44: Women Infertility – Pipeline by Ferring Pharmaceuticals Inc, 2022
- Table 45: Women Infertility – Pipeline by Forendo Pharma Ltd, 2022
- Table 46: Women Infertility – Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
- Table 47: Women Infertility – Pipeline by Genome & Co, 2022
- Table 48: Women Infertility – Pipeline by Glycotope GmbH, 2022
- Table 49: Women Infertility – Pipeline by Hangzhou Metai Pharmaceutical Technology Co Ltd, 2022
- Table 50: Women Infertility – Pipeline by Hope Medicine Inc, 2022
- Table 51: Women Infertility – Pipeline by Igenomix SL, 2022
- Table 52: Women Infertility – Pipeline by Igyxos SA, 2022
- Table 53: Women Infertility – Pipeline by Immunitor Inc, 2022
- Table 54: Women Infertility – Pipeline by Insud Pharma, 2022
- Table 55: Women Infertility – Pipeline by Ironwood Pharmaceuticals Inc, 2022
- Table 56: Women Infertility – Pipeline by Isifer AB, 2022
- Table 57: Women Infertility – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 58: Women Infertility – Pipeline by Kissei Pharmaceutical Co Ltd, 2022
- Table 59: Women Infertility – Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
- Table 60: Women Infertility – Pipeline by Luye Pharma Group Ltd, 2022
- Table 61: Women Infertility – Pipeline by Medibiofarma SL, 2022
- Table 62: Women Infertility – Pipeline by Mithra Pharmaceuticals SA, 2022
- Table 63: Women Infertility – Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
- Table 64: Women Infertility – Pipeline by Myovant Sciences Ltd, 2022
- Table 65: Women Infertility – Pipeline by Navad Life Sciences Pte Ltd, 2022
- Table 66: Women Infertility – Pipeline by Neuromagen Pharma Ltd, 2022
- Table 67: Women Infertility – Pipeline by Nippon Shinyaku Co Ltd, 2022
- Table 68: Women Infertility – Pipeline by NutriBand Inc, 2022
- Table 69: Women Infertility – Pipeline by ObsEva SA, 2022
- Table 70: Women Infertility – Pipeline by Oxolife SL, 2022
- Table 71: Women Infertility – Pipeline by Pangen Biotech Inc, 2022
- Table 72: Women Infertility – Pipeline by Park of Active Molecules, 2022
- Table 73: Women Infertility – Pipeline by Pharmasyntez, 2022
- Table 74: Women Infertility – Pipeline by Predictive Therapeutics LLC, 2022
- Table 75: Women Infertility – Pipeline by PregLem SA, 2022
- Table 76: Women Infertility – Pipeline by Reven Holdings Inc, 2022
- Table 77: Women Infertility – Pipeline by Shandong TheraWisdom Biopharma Co Ltd, 2022
- Table 78: Women Infertility – Pipeline by Shanghai Jing Ze Biotechnology Co Ltd, 2022
- Table 79: Women Infertility – Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, 2022
- Table 80: Women Infertility – Pipeline by Suzhou JiSheng Pharmaceutical Co Ltd, 2022
- Table 81: Women Infertility – Pipeline by SYNG Pharmaceuticals Inc, 2022
- Table 82: Women Infertility – Pipeline by Synokem Pharmaceuticals Ltd, 2022
- Table 83: Women Infertility – Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Table 84: Women Infertility – Pipeline by Temple Therapeutics BV, 2022
- Table 85: Women Infertility – Pipeline by TiumBio Co Ltd, 2022
- Table 86: Women Infertility – Pipeline by Trophogen Inc, 2022
- Table 87: Women Infertility – Pipeline by Unicohealth Pharma Co Ltd, 2022
- Table 88: Women Infertility – Pipeline by ValiRx Plc, 2022
- Table 89: Women Infertility – Pipeline by Viramal Ltd, 2022
- Table 90: Women Infertility – Pipeline by Xbrane Biopharma AB, 2022
- Table 91: Women Infertility – Dormant Projects, 2022
- Table 92: Women Infertility – Dormant Projects, 2022 (Contd..1)
- Table 93: Women Infertility – Dormant Projects, 2022 (Contd..2)
- Table 94: Women Infertility – Dormant Projects, 2022 (Contd..3)
- Table 95: Women Infertility – Dormant Projects, 2022 (Contd..4)
- Table 96: Women Infertility – Discontinued Products, 2022
- Table 97: Women Infertility – Discontinued Products, 2022 (Contd..1)
- List of Figures
- Figure 1: Number of Products under Development for Women Infertility, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.